Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast in NASH
NCT06677788Phase 2Completed
- Sponsor
- Tanta University
- Start
- Apr 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of roflumilast in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Tanta University. Primary endpoint: Change in liver stiffness measurement at 12 weeks. Started Apr 2022; status: completed.
02
Drugs
roflumilast
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06677788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06677788.